Fig. 2From: Comparative efficacy and safety of paricalcitol versus vitamin D receptor activators for dialysis patients with secondary hyperparathyroidism: a meta-analysis of randomized controlled trialsEffect of paricalcitol on suppressing iPTH as compared to other VDRAsBack to article page